Clinical efficacy of ceftazidime combined with levofloxacin on heart failure complicated with pulmonary infection and its influence on cardiopulmonary function.

Rong Yang, Yuou Li, Jinliang Li, Limin Xing, Li Liu

Open access · greenAbstract read

In one paragraph

Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 93% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Rong YangDepartment of Fundamental Medicine, Hubei College of Chinese Medicine Jingzhou 434020, Hubei Province, China.

Yuou LiDepartment of Outpatient, Harbin Sixth Hospital Harbin 150040, Heilongjiang Province, China.

Jinliang LiDepartment of General Internal Medicine, Harbin Sixth Hospital Harbin 150040, Heilongjiang Province, China.

Limin XingDepartment of Nursing, Xiangyang No. 1 People's Hospital Affiliated to Hubei University of Medicine Xiangyang 441000, Hubei Province, China.

Li LiuDepartment of Cardiothoracic Surgery, Xiangyang No. 1 People's Hospital Affiliated to Hubei University of Medicine Xiangyang 441000, Hubei Province, China.

Heilongjiang Provincial Hospital · CNHubei University of Medicine · CNHubei University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study was designed to analyze the clinical efficacy of ceftazidime combined with levofloxacin on heart failure complicated with pulmonary infection and its influence on cardiopulmonary function.

methodsA total of 124 patients with heart failure and pulmonary infection admitted to our hospital from June 2018 to October 2019 were divided into groups according to different treatment schemes. Thereinto, 60 patients who were given ceftazidime intravenous drip on the basis of routine treatment were included in group A, and 64 who were given levofloxacin hydrochloride injection based on intravenous drip in group A were included in group B. The clinical efficacy, cardiac and lung function, pathogenic bacteria, infection, immune indexes and adverse reactions before and after treatment were compared.

resultsAfter treatment, the adjusted levels of LVEF, LVEDD and LA in group B after treatment were greater than those in group A (P<0.05); the levels of MMV, TLC and FEV1 in group B were increased more than those in group A (P<0.05). After treatment, the levels of BNP, PCT and CRP in groups A and B decreased compared with those before treatment (P<0.05). Furthermore, the down-regulated levels of BNP, PCT and CRP in group B were higher than those in group A after treatment (P<0.05). After treatment, the levels of serum CD3

conclusionTo sum up, ceftazidime combined with levofloxacin on patients with heart failure and pulmonary infection can improve the immune function while optimizing the clinical efficacy and cardiopulmonary function.

Indexed as

cardiopulmonary functionCeftazidimeheart failurelevofloxacinpulmonary infection

Identifiers

PMID34017418

PMCPMC8129224

OpenAlexW3160974036

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.